|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...6061626364656667686970...156157» |
- gimsilumab (KIN-1901) / Roivant, Eisai
Trial initiation date: MORAB022-001: Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects (clinicaltrials.gov) - Jul 20, 2015
P1, N=20, Completed, Sponsor: Morphotek
Initiation date: May 2013 --> Jun 2010
- |||||| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Enrollment open: DEPICT 2: Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (clinicaltrials.gov) - Jul 20, 2015
P3, N=768, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: May 2013 --> Jun 2010 Not yet recruiting --> Recruiting
- Enrollment closed: A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects (clinicaltrials.gov) - Jul 20, 2015
P1, N=44, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Betaseron (IFN-β-1b) / Bayer
Trial primary completion date, Adherence: BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon (clinicaltrials.gov) - Jul 17, 2015
P=N/A, N=450, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2016 --> Jun 2016
- Trial completion, Enrollment change, Biopsy: Temporal Artery Biopsy vs ULtrasound in Diagnosis of GCA (TABUL) (clinicaltrials.gov) - Jul 17, 2015
P=N/A, N=880, Completed, Sponsor: University of Oxford
Trial primary completion date: Mar 2016 --> Jun 2016 Recruiting --> Completed | N=700 --> 880
- | ceralifimod (ONO 4641) / Ono Pharma
Trial termination, Trial primary completion date: DreaMS: Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Jul 17, 2015
P2, N=343, Terminated, Sponsor: EMD Serono
Active, not recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Dec 2014; Merck has decided to not pursue phase 3 development of ceralifimod (ONO-4641). The decision was not related to any safety and efficacy findings
- | Symlin (pramlintide) / AstraZeneca
New P1 trial: Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jul 17, 2015
P1, N=30, Not yet recruiting, Sponsor: AstraZeneca
- PF530 (interferon beta-1b biosimilar) / Ligand
Enrollment closed: Comparison Study of PF530 and Betaferon in Healthy Subjects (clinicaltrials.gov) - Jul 17, 2015
P1, N=12, Active, not recruiting, Sponsor: Pfenex, Inc
The decision was not related to any safety and efficacy findings Recruiting --> Active, not recruiting
- Orencia (abatacept) / BMS
Trial completion, Enrollment change, MRI: Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients (clinicaltrials.gov) - Jul 17, 2015
P3, N=39, Completed, Sponsor: Arthritis & Rheumatic Disease Specialties Research
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=30 --> 39
- Trial primary completion date: A Clinical Investigation of the Discovery™ Elbow System (clinicaltrials.gov) - Jul 16, 2015
P=N/A, N=120, Active, not recruiting, Sponsor: Biomet Orthopedics, LLC
Active, not recruiting --> Completed | N=30 --> 39 Trial primary completion date: Jun 2015 --> Jun 2016
- Nulojix (belatacept) / BMS
New trial: Safety Profile of Nulojix in Home Infusion Settings (clinicaltrials.gov) - Jul 16, 2015
P=N/A, N=37, Completed, Sponsor: Bristol-Myers Squibb
- | Enrollment open: Project JAY THA Registration Study (clinicaltrials.gov) - Jul 16, 2015
P3, N=96, Recruiting, Sponsor: Smith & Nephew Orthopaedics (Beijing) Limited
Trial primary completion date: Jun 2015 --> Jun 2016 Not yet recruiting --> Recruiting
- | AMG 357 / Amgen
New P1 trial: Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 16, 2015
P1, N=32, Recruiting, Sponsor: Amgen
- | Trial completion, Trial primary completion date: Therapeutic Plasma Exchange in MG (clinicaltrials.gov) - Jul 16, 2015
P=N/A, N=11, Completed, Sponsor: Duke University
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Oct 2014
- Enrollment open: ADT: Assistive Device Training in Multiple Sclerosis (clinicaltrials.gov) - Jul 15, 2015
P=N/A, N=40, Recruiting, Sponsor: Portland VA Medical Center
Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Oct 2014 Not yet recruiting --> Recruiting
- ||||||| Nplate (romiplostim) / Amgen, Kyowa Kirin
Trial completion: Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients (clinicaltrials.gov) - Jul 15, 2015
P3, N=62, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Campath (alemtuzumab) / Sanofi
Enrollment change, Trial withdrawal, Trial primary completion date: Allogeneic Stem Cell Transplantation in Systemic Lupus Erythematosus (clinicaltrials.gov) - Jul 15, 2015
P1, N=0, Withdrawn, Sponsor: Northwestern University
Active, not recruiting --> Completed N=10 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2016 --> Jul 2015
- || BIIB023 / Biogen
Trial primary completion date: ATLAS: BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis (clinicaltrials.gov) - Jul 14, 2015
P2, N=211, Recruiting, Sponsor: Biogen
N=10 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2016 --> Jul 2015 Trial primary completion date: Sep 2016 --> Dec 2016
- ||| remtolumab (ABT-122) / AbbVie
P2 data, Enrollment change: Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study (clinicaltrials.gov) - Jul 14, 2015
P2, N=115, Enrolling by invitation, Sponsor: AbbVie
Trial primary completion date: Sep 2016 --> Dec 2016 N=80 --> 115
- ATX-MS-1467 / Apitope
Enrollment closed: ATX-MS-1467 in Multiple Sclerosis (clinicaltrials.gov) - Jul 14, 2015
P2, N=17, Active, not recruiting, Sponsor: Merck KGaA
N=80 --> 115 Recruiting --> Active, not recruiting
- Lantus (insulin glargine) / Sanofi, Lusduna (insulin glargine biosimilar) / Samsung
Trial primary completion date: A Study of the Safety and Efficacy of MK-1293 Compared to Lantus (clinicaltrials.gov) - Jul 14, 2015
P3, N=500, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Trial primary completion date: May 2015 --> Nov 2015
- || Trial primary completion date: Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents (clinicaltrials.gov) - Jul 14, 2015
P=N/A, N=150, Active, not recruiting, Sponsor: AbbVie
Trial primary completion date: May 2015 --> Nov 2015 Trial primary completion date: Jun 2015 --> Sep 2015
- ||| New trial: Shared Medical Decision Making in Pediatric Diabetes (clinicaltrials.gov) - Jul 14, 2015
P=N/A, N=166, Enrolling by invitation, Sponsor: Nemours Children's Clinic
- |||||| Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Clinical: Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2) (clinicaltrials.gov) - Jul 14, 2015
P3, N=720, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Jun 2015 --> Sep 2015 Not yet recruiting --> Recruiting
- || Tysabri (natalizumab) / Biogen, Royalty
Enrollment closed, Enrollment change, Trial primary completion date: STRIVE: Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants (clinicaltrials.gov) - Jul 14, 2015
P=N/A, N=229, Active, not recruiting, Sponsor: Biogen
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=300 --> 229 | Trial primary completion date: Dec 2016 --> Nov 2018
- | minocycline / Generic mfg.
Trial completion: MinoCIS: Minocycline in Clinically Isolated Syndromes (CIS) (clinicaltrials.gov) - Jul 14, 2015
P3, N=140, Completed, Sponsor: Dr. Luanne Metz
Recruiting --> Active, not recruiting | N=300 --> 229 | Trial primary completion date: Dec 2016 --> Nov 2018 Active, not recruiting --> Completed
- || Tysabri (natalizumab) / Biogen, Royalty
Enrollment closed, Enrollment change, Trial primary completion date: Ireland Natalizumab (TYSABRI) Observational Program (clinicaltrials.gov) - Jul 13, 2015
P=N/A, N=191, Active, not recruiting, Sponsor: Biogen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=1000 --> 191 | Trial primary completion date: Sep 2017 --> Dec 2017
- Enrollment closed: Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial (clinicaltrials.gov) - Jul 13, 2015
P4, N=50, Active, not recruiting, Sponsor: Brigham and Women's Hospital
Recruiting --> Active, not recruiting | N=1000 --> 191 | Trial primary completion date: Sep 2017 --> Dec 2017 Recruiting --> Active, not recruiting
- || Tysabri (natalizumab) / Biogen, Royalty
Enrollment closed, Enrollment change: STRATIFY-2: JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab (clinicaltrials.gov) - Jul 13, 2015
P=N/A, N=36065, Active, not recruiting, Sponsor: Biogen
Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting | N=8000 --> 36065
- ||||||| Rebif (human IFN-β-1a) / EMD Serono
Trial completion: Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Jul 13, 2015
P3, N=260, Completed, Sponsor: EMD Serono
Enrolling by invitation --> Active, not recruiting | N=8000 --> 36065 No longer recruiting --> Completed
- || Enrollment change, Trial primary completion date: Pilot Tape Harvesting Study (clinicaltrials.gov) - Jul 13, 2015
P=N/A, N=55, Recruiting, Sponsor: Biogen
No longer recruiting --> Completed N=40 --> 55 | Trial primary completion date: May 2015 --> Dec 2015
- ianalumab (VAY736) / MorphoSys, Novartis
New P1/2 trial: Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sj (clinicaltrials.gov) - Jul 13, 2015
P1/2, N=25, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion: Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) (clinicaltrials.gov) - Jul 13, 2015
P3, N=185, Completed, Sponsor: Allergan
N=40 --> 55 | Trial primary completion date: May 2015 --> Dec 2015 Active, not recruiting --> Completed
- Saphnelo (anifrolumab) / AstraZeneca
Trial completion, Trial primary completion date: MUSE: A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus (clinicaltrials.gov) - Jul 13, 2015
P2, N=626, Completed, Sponsor: MedImmune LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Apr 2015
- Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment open: Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jul 12, 2015
P1, N=30, Recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Apr 2015 Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Roche
Enrollment change, Trial termination, Trial primary completion date: RITULUP: Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy (clinicaltrials.gov) - Jul 10, 2015
P3, N=9, Terminated, Sponsor: Fundaci
Not yet recruiting --> Recruiting N=36 --> 9 | Recruiting --> Terminated | Trial primary completion date: Nov 2013 --> Nov 2014; The recruitment period has finished without reaching sample size
- | Trial completion, Trial primary completion date: Acetabular Shell Positioning Using Patient Specific Instruments (clinicaltrials.gov) - Jul 10, 2015
P1, N=36, Completed, Sponsor: The Cleveland Clinic
N=36 --> 9 | Recruiting --> Terminated | Trial primary completion date: Nov 2013 --> Nov 2014; The recruitment period has finished without reaching sample size Active, not recruiting --> Completed | Trial primary completion date: Jan 2013 --> Apr 2012
- Tcelna (imilecleucel-T) / Acer Therap, EMD Serono
Trial primary completion date: Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jul 9, 2015
P2, N=180, Active, not recruiting, Sponsor: Opexa Therapeutics, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Jan 2013 --> Apr 2012 Trial primary completion date: Dec 2015 --> Aug 2016
- Trial primary completion date: A Study of Flt3-Ligand Levels in Sjögrens Syndrome (clinicaltrials.gov) - Jul 9, 2015
P=N/A, N=50, Recruiting, Sponsor: Göteborg University
Trial primary completion date: Dec 2015 --> Aug 2016 Trial primary completion date: Jun 2015 --> Jun 2016
- ||| Biomarker, New trial: The Correlation of Periostin and Renal Pathology in Chronic Kidney Disease Patients (clinicaltrials.gov) - Jul 9, 2015
P=N/A, N=100, Completed, Sponsor: Chulalongkorn University
- New trial: DTC: Dual Task Cost in the Upper Limb in Persons With Multiple Sclerosis (clinicaltrials.gov) - Jul 9, 2015
P=N/A, N=60, Not yet recruiting, Sponsor: Hasselt University
- ||| Trial completion, Trial primary completion date: Tight Control of Disease Activity Among Patients With RA Based on a Systematic Telemedicine Treatment Strategy (clinicaltrials.gov) - Jul 9, 2015
P=N/A, N=300, Completed, Sponsor: University of Aarhus
Trial primary completion date: Jun 2015 --> Jun 2016 Recruiting --> Completed | Trial primary completion date: Sep 2015 --> May 2014
- | Epratucyn (epratuzumab) / Gilead
Trial completion: EMBODY 1: Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (clinicaltrials.gov) - Jul 9, 2015
P3, N=793, Completed, Sponsor: UCB Pharma
Recruiting --> Completed | Trial primary completion date: Sep 2015 --> May 2014 Active, not recruiting --> Completed
- minocycline / Generic mfg.
Trial primary completion date: MinoCIS: Minocycline in Clinically Isolated Syndromes (CIS) (clinicaltrials.gov) - Jul 9, 2015
P3, N=154, Active, not recruiting, Sponsor: Dr. Luanne Metz
Active, not recruiting --> Completed Trial primary completion date: Mar 2015 --> Dec 2014
- decitabine / Generic mfg.
Enrollment change, Trial initiation date, Trial primary completion date: A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia (clinicaltrials.gov) - Jul 9, 2015
P2, N=20, Recruiting, Sponsor: Shandong University
Trial primary completion date: Mar 2015 --> Dec 2014 N=60 --> 20 | Initiation date: Jun 2013 --> Jun 2014 | Trial primary completion date: Dec 2015 --> Dec 2016
- | Enbrel (etanercept) / Pfizer, Amgen
Phase classification: Study to Observe the Safety and Efficacy of Etanercept (Enbrel (clinicaltrials.gov) - Jul 9, 2015
P=N/A, N=120, Recruiting, Sponsor: Pfizer
N=60 --> 20 | Initiation date: Jun 2013 --> Jun 2014 | Trial primary completion date: Dec 2015 --> Dec 2016 Phase classification: P4 --> P=N/A
- dapsone / Generic mfg.
New P1 trial: Pharmacokinetics and Distribution of Dapsone in Leucocytes After Single-dose and Multiple-dose Administration (clinicaltrials.gov) - Jul 9, 2015
P1, N=23, Completed, Sponsor: University Medicine Greifswald
- Venclexta (venetoclax) / Roche, AbbVie
Trial completion: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Jul 9, 2015
P1, N=97, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Phase classification: P4 --> P=N/A Recruiting --> Completed
- Tysabri (natalizumab) / Biogen, Royalty
Enrollment change, Trial termination, Trial primary completion date: SIMPLIFY: Natalizumab Subcutaneous Immunogenicity and Safety Study (clinicaltrials.gov) - Jul 8, 2015
P2, N=2, Terminated, Sponsor: Biogen
Recruiting --> Completed N=113 --> 2 | Not yet recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Nov 2016; Sponsor's decision.
- prednisone delayed-release tablet / Generic mfg.
Trial completion, Trial primary completion date: Efficacy of Lodotra (clinicaltrials.gov) - Jul 8, 2015
P4, N=147, Completed, Sponsor: Mundipharma Korea Ltd
N=113 --> 2 | Not yet recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Nov 2016; Sponsor's decision. Recruiting --> Completed | Trial primary completion date: May 2014 --> Apr 2015